GSK is currently the market leader in the meningococcal vaccine market, racking up sales of £1.26 billion (almost $1.6 billion) last year across the Bexsero and Menveo brands, but is having to ...
The pneumococcus (pneumonia) vaccine is recommended for children younger than 5 years and adults 50 years or older. This is an update to previous guidance, which called for vaccines in adults 65 ...
The company has previously suggested that the 5-in-1 vaccine could eventually become a $1 billion to $2 billion product. Investigator sites are essential for successful execution of clinical ...
Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...